put flesh bone
bonesupport share impress run doubl
sinc june initi manag present recent capit market day
stockholm london suggest compani earli stage plan
exploit full potenti cerament wider opportun global bone
void filler market key outcom summer strateg review focu
strengthen optimis us european commerci footprint solid
commerci foundat coupl near-term clinic heor data read out
enabl bonesupport leav behind challeng transit
new growth phase upgrad valuat
share back recent progress better growth prospect
signific invest commerci footprint expand experienc
focus sale platform central achiev sale compound-annual-growth-rate target
us new direct sale model independ distributor
rep return cerament bvf sale growth improv margin market
access ahead new product launch particular potenti cerament us
launch europ plan new hire place improv
coverag key hospit focu market eg germani trauma
clinic heor data amplifi kol payor support market initi
build kol support key region plan around level trial read out top-
line certifi data could posit cerament bvf new standard
care trauma fortifi recruit remain track plan cerament
pma file posit outcom studi coupl health technolog
assess determin reimburs price uptak
market led approach innov move one platform broad product
offer transform bonesupport orthobiolog player address
segment global bone graft market see us launch synergist
osteogenic/osteoinduct product acquir collagen matrix mtf
biolog alongsid next wave launch includ new cerament
formul procedur kit rang indic innov
osteoinduct product proprietari pipelin long-term prospect
valuat upgrad revisit forecast given
signific near-term commerci invest increas mid- long-term sale
continu use three-phas dcf methodolog explicit forecast
trend period termin growth rate
discount rate gener valuat
near-term upsid potenti come commerci execut certifi data
new us product launch fortifi key long-term growth driver
share issu
bonesupport swedish ortho-
biolog compani focus
develop commercialis
pipelin uniqu inject drug
substitut base proprietari
triniti delta strategi deliv sale
compound-annual-growth-rate
ambit becom lead
growth strategi address
three pillar busi model
optimis commerci
platform near-term
provid firm foundat
futur product launch
bonesupport clear roadmap growth
bonesupport embark sever new initi acceler us
european market penetr cerament uniqu inject drug elut
synthet bone graft substitut sustain boost sale year
transit compani defin start implement focus
growth strategi aim sale compound-annual-growth-rate onward
recent capit market event stockholm london first opportun
manag outlin find strateg review carri
summer provid detail next step bonesupport seek
becom global orthobiolog leader also allow compani
showcas cerament uniqu valu proposit demonstr depth
breadth manag
addit ceo emil billbck present given two key opinion
univers hospit professor venu kavarthapu senior consult surgeon
king colleg hospit london well bjrn westberg cfo dr michael
diefenbeck head medic clinic affair patrick odonnel
focu guid principl bonesupport compani appreci
broad applic product clearli defin activ
maximum influenc long-term growth potenti strategi
address three pillar bonesupport busi model innov
lead clinic evid heor health econom outcom research data
effect commerci platform consid turn expand
later report highlight signific progress optimis
us european commerci footprint
prioritis commerci execut like greatest impact growth
short-term well lay firm foundat futur growth recent
invest expand global footprint greater emphasi penetr
market opportun complex trauma mean well posit benefit
level clinic data data cerament fortifi trial
cerament bvf certifi trial acceler sale
provid competit differenti larg trauma market us
plan launch cerament assum pma approv repres
key inflect point bonesupport interim compani benefit
oper leverag us launch new complementari product
acquir collagen matrix mtf biolog follow new
strateg roadmap allow bonesupport leav behind period
uncertainti associ impact zimmer biomet hardwar suppli issu
us sale subsequ termin
distribut agreement uncertainti weigh share price perform
reach low june howev ralli sinc late summer
testament wider appreci strategi grow confid
manag deliv cerament growth potenti
believ signific upsid potenti success execut
multipl catalyst exhibit next month
exhibit bonesupport news flow catalyst calendar
cerament bvf first day promot us bonesupport distributor network
result last full quarter us zimmer biomet exclus promot
cerament bvf top-line data certifi cerament treatment fractur defect non-inferior
studi va autograft trauma
initi french chronic osteomyel studi support reimburs
cerament bvf progress gpo contract us
cerament bvf public certifi trauma data
full data nuffield orthopaed centr heor analysi one-stag cerament
treatment vs option osteomyel
april cerament bvf start exclus promot us bonesupport distributor network
target complet enrol fortifi studi tibial fractur
confirm timelin pma file
us launch new collagen matrix mtf biolog product bonesupport brand
complet fortifi trial support fda approv trauma
pma approv launch
cerament first-in-class
bone remodel drug
innov expans product offer
bonesupport cerament platform uniqu valu proposit well
posit address three key challeng orthopaed manag
bone loss bone void bone infect cerament addit two key
differenti properti vs synthet bone void filler clinic proven
remodel host bone within month treat bone loss and/or bone
void elut drugs/biolog directli bone void treat infect
local rather system antibiot deliveri
similar chemic
composit human bone
cerament properti eman chemic composit
blend hydroxyapatit ha -calcium sulphat hemihydr powder
mean close resembl human bone balanc implant resorpt new
bone in-growth support optim bone heal
broad applic potenti
becom game chang
cerament bvf basic bone void filler key market us europ
cerament europ elut antibiot gentamycin
vancomycin respect broad applic across variou orthopaed
indic expert opinion cerament g/v could time becom
new standard care permit one-stag manag bone infect
cerament easi integr
orthopaed practic
broaden product
initi osteogen
osteoinduct product
opinion leader kol present highlight import featur
mean straightforward integr cerament exist practic
closed-mix system easi use drillabl critic use hardwar
trauma radiopaqu facilit use minim invas surgeri set
isotherm risk thermal tissu damag cerament inject
mouldabl compat variou needl size enabl complet fill
void size without necessit bone loss increas
diamet entri hole/cav
bonesupport pursu market-l approach innov continu invest
ensur highli differenti relev product offer
cerament mani posit attribut key limit avail
product address one three mechan via bone
tissu regener replac implant graft osteoconduct
bonesupport explor exploit opportun broaden product
offer synergist product osteogen and/or osteoinduct
properti captur larger share overal bone graft market
near-term opportun complementari product us market
recent acquir collagen matrix mtf biolog exhibit
bonesupport-brand product differ mechan action
cerament bvf osteoconduct launch could also
form basi develop new combin product dual-mechan
strateg deal type could conclud
exhibit expand product offer
osteoinduct
synthet bioceram inject bone void filler ha act long-term
osteoconduct scaffold support bone ingrowth calcium sulphat provid
structur support resorb quickli creat space new bone
tissu grow
demineralis bone matrix dbm bonesupport right two form bone
graft compros dbm dbm contain exogen growth facotor eg
bone morphogenet protein promot mesenchym stem cell differenti
new bone form cell
osteogen
synthet graft deliveri autolog stem cell combin bone
marrow aspir promot synthesi new bone live bone cell osteoblast
origin bone graft materi
avail year
mid-term bonesupport product expans focus new cerament
formul combin present procedur kit rang
substitut carri procedur henc bundl offer conveni
time profit advantag us product sold
sale call point indic potenti synergist
cerament therefor expect hear futur product
categori tie-up hardwar manufactur close
lastli long-term opportun eman bonesupport in-hous
research novel osteoinduct product design enhanc bone growth
novel proprietari product
innov pipelin consist four product exploit cerament drug-
elut properti combin approv therapi bisphosphon
zoledron acid bone morphogen protein stem cell bone marrow
reimburs price first expect enter clinic
med-tech
autograft
fortifi result
clinic outcom data also
lead clinic evid heor data
bonesupport appli big pharma approach orthopaed market
data-driven strategi improv reimburs acceler cerament
penetr exist broader indic extens data set
includ peer review public abstract industri
lead provid compel evid support util cerament
posit vs altern data includ case studi trial registri
soon includ level evid on-going randomis clinic trial
orthopaed compani made similar invest clinic
data literatur review reveal market bone graft substitut
clinic data
key trauma trial certifi fortifi
trauma major market opportun cerament bonesupport invest
two major studi compar clinic outcom versu bvf addit
standard care support us approv cerament posit data
shine spotlight cerament benefit vs altern support
reimburs show posit impact hospit cost
drive increas usag kol larger orthopaed trauma centr
certifi studi across german trauma centr bonesupport
first larg randomis prospect trial trauma tibial fractur non-
inferior studi compar cerament bvf vs gold standard autograft
sever endpoint pain qualiti life cost care autograft patient-deriv
bone graft two-step procedur harvest graft often associ
pain donor site certifi fulli enrol top line data expect
public full studi result
fortifi studi across global trauma centr evalu
addit cerament standard care intermedullari nail surgic
repair open diaphys tibial fractur design demonstr
efficaci cerament complex yet common trauma indic
patient risk develop bone infect posit data would provid
proof concept prophylact use add standard treatment
fortifi enrol plan recruit expect complet
one-year follow avail data form part fda
submiss final pma modul cerament year
data trial also support improv reimburs cerament
trauma cerament bvf bone remodel properti combin similar
better clinic outcom current gold standard cheaper cost
without associ disadvantag autograft would attract
proposit surgeon hospit cerament gs antibiot elut
capabl provid signific addit benefit improv protect
bone heal process reduc incid complic eg fractur non-
union deep infect lead hospit readmiss
triniti delta cerament reduc length
hospit stay associ
heath econom outcom research focu cerament
cerament g/v abil treat chronic bone infect lower risk
infect hospit readmiss high risk injuri import
differenti healthcar market move toward goal reduc
surgic time total cost care deliv improv patient outcom
bone infect signific impact healthcar cost primari
determin cost length stay hospit whether initi
treatment exhibit readmiss treat secondari infect
exhibit cerament g/v manag bone infect cost-effect
one-stag surgeri
analysi avail
key compon cerament
cerament shown benefit patient hospit resourc
reduc length stay success one-stag surgeri
infect patient chronic osteomyel singl stage procedur
cerament focus heor underway europ us result
analys intend support reimburs detail econom analysi
studi led nuffield orthopaed centr oxford univers
hospit becom avail initi data indic use
cerament osteomyel reduc surgic time procedur rate
compar full rang altern treatment avail england
data also relev across contin bonesupport seek improv
reimburs increment code eg pursu ze code germani
well develop tool streamlin file process
heor activ central cerament us launch prepar
bonesupport initi review reimburs access option
intend gener technolog assess public plan
base fortifi data includ readmiss rate total length stay
advers event cost highlight readmiss rate
frequent use qualiti care metric seriou complic often
associ readmiss increas cost treatment coupl
potenti penalti hospit readmiss reduct program
afford act significantli impact hospit profit henc
critic determin reimburs price uptak
triniti delta address market
indic cerament
current address market cerament exclud dental spine
cranio-maxillofaci applic procedur per year although
third utilis synthet bone void substitut autograft allograft
donor bone remain favour option europ repres
procedur despit drawback associ pain two-surgeri
procedur autograft risk diseas transmiss graft failur allograft
use dbm common us procedur compar
europ reflect differ clinic practic wherebi cocktail
sever bone graft substanc typic use us vs singl type europ
exhibit illustr bonesupport segment address opportun
four defin target indic gain market share autograft/allograft
take time although compani identifi immedi opportun
take share synthet bone void filler particularli trauma
osteomyel grow sale optimis commerci platform
exhibit commerci activ focu four target indic
underinvest us
control sale process
higher margin
cerament two key geographi differ dynam differ product
avail thu sale model differ us europ common theme
accord manag under-resourc
rectifi target invest intent develop new
relationship surgeon hospit leverag cerament data
exist kol network broaden penetr across key orthopaed indic
us transit direct sale model
decis termin us cerament bvf distribut agreement
zimmer biomet strateg move re-gain control commercialis
largest orthopaed market global replac direct sale model
bring sever benefit bonesupport includ improv margin
percentag point gross sale greater influenc distribut channel
restrict zimmer biomet call point abil access much
platform place ahead
initi distributor network
octob
us commerci team work
product portfolio improv
almost doubl sale forc
direct countri
impact current under-
importantli switch direct model mean bonesupport
establish fulli oper us platform highli motiv focus
sale forc ahead launch cerament ahead launch
support educ activ commun valu proposit
cerament drug-elut portfolio develop larg potenti custom base
ensur rapid launch trajectori cerament
expiri zimmer biomet exclus octob direct us distribut
cerament bvf begin newli recruit network independ
distributor total sale rep network cover base us
cerament bvf busi zimmer biomet april
sole sourc cerament bvf us time plan expans
distributor depend progress sale penetr term
territori indic
bonesupport also expand us commerci team individu
recruit experienc hire anticip
year-end commerci team work extern consult
put place infrastructur support cerament bvf sale growth includ
enhanc market access contract key us purchas organis
prioriti ensur cerament wide avail aim secur
bonesupport-specif contract initi focu larg gpo group
purchas organis whose hospit member previous purchas
cerament bvf vizient hospit member premier
trust member futur announc
confirm gpo contract secur expect
bonesupport us commerci strategi present opportun oper
leverag broader product offer initi collagen matrix
mtf biolog product portfolio also improv bonesupport competit
posit healthcar gpo integr deliveri network idn
europ expans better penetr major market
bonesupport sell cerament direct five european countri uk germani
switzerland sweden denmark special distributor
non-u countri plan nearli doubl direct european sale organis
track first hire
made expand sale capabl enabl better penetr major
market germani add impetu plan prioritis major indic
invest european sale like reap reward rel short
time-frame new hire experienc deploy key region
import orthopaed centr bonesupport current limit
presenc exhibit illustr concept untap potenti germani
region sale director hire northern region well
sale rep cover berlin dresden frankfurt/cologn
addit region sale director hire southern europ spain
itali franc portug sale rep southern uk stockholm/north
sweden rep hire nordic region commerci
initi drive product includ on-line train direct sale
distributor perform metric distributor
exhibit germani key target market cerament
trauma chronic
osteomyel prioritis
growth prospect evid
execut
ultim goal increas penetr sale cerament g/v
current repres european sale europ establish
foothold chronic osteomyel base strength clinic data kol
support scope penetr indic howev
resourc direct toward under-penetrated larger market
opportun present complex trauma
financi valuat
revisit forecast exhibit follow clear roadmap futur
growth provid manag capit market event importantli
confirm key experienc commerci hire alreadi made
us europ provid us confid deliveri plan
exhibit summari chang estim
uncertainti remain
long-term prospect
cerament rosi
continu view year transit short-term uncertainti
surround us cerament bvf sale cancel zimmer biomet
order run inventori first week direct sale
make minor chang forecast revis long-term
assess cerament gs prospect europ us driven
greater appreci kol support potenti impact strong fortifi data
heor recent approv health canada expect first sale
canada yet secur distributor
higher assum cost
due fortifi
commerci expans us
meaning chang made cost assumpt increas
forecast spend connect fortifi sek
sek sek sek respect also fine-
tune sale cost sek sek sek
triniti delta new valuat sek
sek reflect time magnitud commerci
expans well tweak us margin assumpt cerament
given confirm sale commiss sale report sg
updat valuat reflect chang forecast assumpt well
roll forward model reflect passag time updat
number share outstand three-stag dcf methodolog valu
bonesupport sek
valuat base explicit cash flow follow ten-year
trend period termin growth rate forecast sale
current market cerament product europe/row us also
includ cerament us latter assum launch
appli risk adjust recognis clinic regulatori risk individu
product rnpv sum net cost run busi
exhibit provid detail breakdown compon valuat
exhibit dcf-base valuat bonesupport
likelihood
net cash
triniti delta note assum usd/sek exchang rate
continu success execut eg commerci traction success addit
product would unlock upsid potenti impact certifi
trajectori bvf sale trauma us approv cerament two key
inflect point latter remov risk adjust cerament
us would lift valuat sek
addit continu appli discount rate reflect fact
bonesupport small compani oper highli competit market use
less conserv discount rate result higher valuat sek
exhibit summari financi
compani triniti delta note histor adjust number share follow
consolid
triniti deltayear-end dec good oper profit financ tax incom ep share marginn/an/an/an/an/an/abal sheetcurr cash current plant non-curr current non-curr statementsoper cash work cash invest cash cash financ cash increas rate start end cash end
triniti delta research limit tdrl firm refer number trade triniti delta appoint repres
equiti develop limit ed content report prepar sole respons tdrl
review independ verifi ed authoris regul fca whose refer number
ed act tdrl person respons provid protect provid client tdrl
advis person connect content report except extent requir applic law
includ rule fca owe duti care person relianc may place ed advic
recommend respect content report extent may applic law ed make
represent warranti person read report regard inform contain
prepar report tdrl use public avail sourc taken reason effort ensur fact state
herein clear fair mislead make guarante warranti accuraci complet inform
opinion contain herein provid updat fresh inform becom avail opinion chang
person relev person section section financi servic market act unit
kingdom act reli document content research client compani produc tdrl normal
commiss paid compani issuer financ research deem independ
defin fca object author state opinion report consid market
commun purpos fca rule prepar accord legal requir design promot
independ invest research subject prohibit deal ahead dissemin invest research
tdrl hold posit compani mention report although director employe consult tdrl
may hold posit compani mention tdrl impos restrict person deal tdrl might also provid servic
compani mention solicit busi
report provid relev person provid background inform subject matter note document
constitut form part constru offer sale purchas solicit invit
make offer buy sell secur may rise fall valu shall part form basi reli
connect contract commit whatsoev inform provid intend
manner whatsoev constru personalis advic self-certif investor complet free charg
www fisma org tdrl affili offic director employe ed liabl loss damag aris use
document maximum extent law permit
inform avail websit www trinitydelta org
